

Brendan D Manning

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9046136/publications.pdf>

Version: 2024-02-01

110
papers

33,648
citations

16791

66
h-index

27587

110
g-index

133
all docs

133
docs citations

133
times ranked

46810
citing authors

#	ARTICLE	IF	CITATIONS
1	AKT/PKB Signaling: Navigating Downstream. <i>Cell</i> , 2007, 129, 1261-1274.	13.5	5,261
2	AKT/PKB Signaling: Navigating the Network. <i>Cell</i> , 2017, 169, 381-405.	13.5	2,454
3	Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1. <i>Molecular Cell</i> , 2010, 39, 171-183.	4.5	1,598
4	Identification of the Tuberous Sclerosis Complex-2 Tumor Suppressor Gene Product Tuberin as a Target of the Phosphoinositide 3-Kinase/Akt Pathway. <i>Molecular Cell</i> , 2002, 10, 151-162.	4.5	1,376
5	Targeting the PI3K-Akt pathway in human cancer. <i>Cancer Cell</i> , 2003, 4, 257-262.	7.7	1,230
6	Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. <i>Genes and Development</i> , 2004, 18, 2893-2904.	2.7	1,166
7	The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. <i>Nature Reviews Cancer</i> , 2020, 20, 74-88.	12.8	1,087
8	Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb. <i>Current Biology</i> , 2003, 13, 1259-1268.	1.8	1,047
9	The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. <i>Biochemical Journal</i> , 2008, 412, 179-190.	1.7	1,045
10	The LKB1 tumor suppressor negatively regulates mTOR signaling. <i>Cancer Cell</i> , 2004, 6, 91-99.	7.7	956
11	Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13571-13576.	3.3	744
12	Spatial Control of the TSC Complex Integrates Insulin and Nutrient Regulation of mTORC1 at the Lysosome. <i>Cell</i> , 2014, 156, 771-785.	13.5	625
13	A complex interplay between Akt, TSC2 and the two mTOR complexes. <i>Biochemical Society Transactions</i> , 2009, 37, 217-222.	1.6	623
14	Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1. <i>Science</i> , 2013, 339, 1323-1328.	6.0	596
15	Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. <i>Nature Cell Biology</i> , 2013, 15, 555-564.	4.6	595
16	mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. <i>Science</i> , 2016, 351, 728-733.	6.0	585
17	Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. <i>Nature Cell Biology</i> , 2014, 16, 1069-1079.	4.6	534
18	Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways. <i>Cell Metabolism</i> , 2011, 14, 21-32.	7.2	511

#	ARTICLE	IF	CITATIONS
19	TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1. <i>Molecular Cell</i> , 2012, 47, 535-546.	4.5	509
20	mTORC1 signaling and the metabolic control of cell growth. <i>Current Opinion in Cell Biology</i> , 2017, 45, 72-82.	2.6	465
21	The TSC-mTOR pathway regulates macrophage polarization. <i>Nature Communications</i> , 2013, 4, 2834.	5.8	459
22	Balancing Akt with S6K. <i>Journal of Cell Biology</i> , 2004, 167, 399-403.	2.3	450
23	The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2. <i>Molecular and Cellular Biology</i> , 2008, 28, 4104-4115.	1.1	444
24	Rheb fills a GAP between TSC and TOR. <i>Trends in Biochemical Sciences</i> , 2003, 28, 573-576.	3.7	443
25	Loss of the Tuberous Sclerosis Complex Tumor Suppressors Triggers the Unfolded Protein Response to Regulate Insulin Signaling and Apoptosis. <i>Molecular Cell</i> , 2008, 29, 541-551.	4.5	389
26	Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1. <i>Molecular and Cellular Biology</i> , 2009, 29, 5657-5670.	1.1	388
27	Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. <i>Human Molecular Genetics</i> , 2005, 14, R251-R258.	1.4	343
28	Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. <i>ELife</i> , 2016, 5, .	2.8	324
29	Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway. <i>PLoS ONE</i> , 2009, 4, e6189.	1.1	306
30	Coordinated regulation of protein synthesis and degradation by mTORC1. <i>Nature</i> , 2014, 513, 440-443.	13.7	292
31	Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. <i>Cell Metabolism</i> , 2017, 25, 463-471.	7.2	281
32	mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. <i>Trends in Endocrinology and Metabolism</i> , 2011, 22, 94-102.	3.1	280
33	Oncogenic EGFR Signaling Activates an mTORC2- $\text{NF-}\kappa\text{B}$ Pathway That Promotes Chemotherapy Resistance. <i>Cancer Discovery</i> , 2011, 1, 524-538.	7.7	275
34	NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth. <i>Molecular and Cellular Biology</i> , 2009, 29, 4250-4261.	1.1	264
35	S6K1 Regulates GSK3 under Conditions of mTOR-Dependent Feedback Inhibition of Akt. <i>Molecular Cell</i> , 2006, 24, 185-197.	4.5	260
36	Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors. <i>Cancer Cell</i> , 2011, 20, 400-413.	7.7	231

#	ARTICLE	IF	CITATIONS
37	Amino Acid Restriction Triggers Angiogenesis via GCN2/ATF4 Regulation of VEGF and H2S Production. <i>Cell</i> , 2018, 173, 117-129.e14.	13.5	229
38	The multifaceted role of mTORC1 in the control of lipid metabolism. <i>EMBO Reports</i> , 2013, 14, 242-251.	2.0	219
39	Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. <i>Genes and Development</i> , 2005, 19, 1773-1778.	2.7	216
40	Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. <i>Nature Cell Biology</i> , 2013, 15, 1340-1350.	4.6	216
41	United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. <i>Biochemical Society Transactions</i> , 2003, 31, 573-578.	1.6	204
42	Molecular logic of mTORC1 signalling as a metabolic rheostat. <i>Nature Metabolism</i> , 2019, 1, 321-333.	5.1	197
43	Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. <i>Oncogene</i> , 2016, 35, 1250-1260.	2.6	189
44	The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. <i>Cancer Cell</i> , 2006, 10, 133-143.	7.7	180
45	Genomic complexity and plasticity of <i>Burkholderia cepacia</i> . <i>FEMS Microbiology Letters</i> , 1996, 144, 117-128.	0.7	174
46	mTOR links oncogenic signaling to tumor cell metabolism. <i>Journal of Molecular Medicine</i> , 2011, 89, 221-228.	1.7	158
47	Chronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in Mice. <i>Science Signaling</i> , 2012, 5, ra24.	1.6	157
48	Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in <i>C. elegans</i> . <i>Nature</i> , 2017, 541, 102-106.	13.7	152
49	The mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels. <i>Cell Reports</i> , 2017, 21, 1331-1346.	2.9	149
50	A growing role for mTOR in promoting anabolic metabolism. <i>Biochemical Society Transactions</i> , 2013, 41, 906-912.	1.6	148
51	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017, 547, 109-113.	13.7	142
52	Transcriptional Control of Cellular Metabolism by mTOR Signaling. <i>Cancer Research</i> , 2011, 71, 2815-2820.	0.4	135
53	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2013, 3, 870-879.	7.7	127
54	A relative quantitative positive/negative ion switching method for untargeted lipidomics via high resolution LC-MS/MS from any biological source. <i>Metabolomics</i> , 2017, 13, 1.	1.4	124

#	ARTICLE	IF	CITATIONS
55	Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi. <i>Science Signaling</i> , 2015, 8, rs9.	1.6	113
56	ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis. <i>Genes and Development</i> , 2014, 28, 1917-1928.	2.7	109
57	mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability. <i>Cancer Cell</i> , 2017, 32, 624-638.e5.	7.7	109
58	Ex vivo and in vivo stable isotope labelling of central carbon metabolism and related pathways with analysis by LC-MS/MS. <i>Nature Protocols</i> , 2019, 14, 313-330.	5.5	106
59	The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals. <i>ELife</i> , 2021, 10, .	2.8	105
60	Signaling Events Downstream of Mammalian Target of Rapamycin Complex 2 Are Attenuated in Cells and Tumors Deficient for the Tuberous Sclerosis Complex Tumor Suppressors. <i>Cancer Research</i> , 2009, 69, 6107-6114.	0.4	102
61	Differential Regulation of the Kar3p Kinesin-related Protein by Two Associated Proteins, Cik1p and Vik1p. <i>Journal of Cell Biology</i> , 1999, 144, 1219-1233.	2.3	100
62	Emerging Role of mTOR in the Response to Cancer Therapeutics. <i>Trends in Cancer</i> , 2016, 2, 241-251.	3.8	95
63	The Rho-GEF Rom2p Localizes to Sites of Polarized Cell Growth and Participates in Cytoskeletal Functions in <i>Saccharomyces cerevisiae</i> . <i>Molecular Biology of the Cell</i> , 1997, 8, 1829-1844.	0.9	94
64	Hitting the Target: Emerging Technologies in the Search for Kinase Substrates. <i>Science Signaling</i> , 2002, 2002, pe49-pe49.	1.6	85
65	Direct stimulation of NAD ⁺ synthesis through Akt-mediated phosphorylation of NAD kinase. <i>Science</i> , 2019, 363, 1088-1092.	6.0	85
66	mTORC1 signaling activates NRF1 to increase cellular proteasome levels. <i>Cell Cycle</i> , 2015, 14, 2011-2017.	1.3	76
67	Low-dose radiation exposure induces a HIF-1-mediated adaptive and protective metabolic response. <i>Cell Death and Differentiation</i> , 2014, 21, 836-844.	5.0	75
68	Fibroblastic reticular cells enhance T cell metabolism and survival via epigenetic remodeling. <i>Nature Immunology</i> , 2019, 20, 1668-1680.	7.0	53
69	The Kar3p Kinesin-related Protein Forms a Novel Heterodimeric Structure with Its Associated Protein Cik1p. <i>Molecular Biology of the Cell</i> , 2000, 11, 2373-2385.	0.9	51
70	Challenges and Opportunities in Defining the Essential Cancer Kinome. <i>Science Signaling</i> , 2009, 2, pe15.	1.6	47
71	Molecular Basis of Giant Cells in Tuberous Sclerosis Complex. <i>New England Journal of Medicine</i> , 2014, 371, 778-780.	13.9	47
72	The TSC Complex Is Required for the Benefits of Dietary Protein Restriction on Stress Resistance In Vivo. <i>Cell Reports</i> , 2014, 8, 1160-1170.	2.9	47

#	ARTICLE	IF	CITATIONS
73	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. <i>Pediatric Neurology</i> , 2016, 60, 1-12.	1.0	43
74	Drivers and passengers wanted! The role of kinesin-associated proteins. <i>Trends in Cell Biology</i> , 2000, 10, 281-289.	3.6	37
75	mTORC1 Status Dictates Tumor Response to Targeted Therapeutics. <i>Science Signaling</i> , 2013, 6, pe31.	1.6	34
76	Tuberous Sclerosis Complex 2 Loss Increases Lysophosphatidylcholine Synthesis in Lymphangioliomyomatosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 53, 33-41.	1.4	30
77	Nutrient Sensing in Cancer. <i>Annual Review of Cancer Biology</i> , 2018, 2, 251-269.	2.3	29
78	Game of TOR "The Target of Rapamycin Rules Four Kingdoms. <i>New England Journal of Medicine</i> , 2017, 377, 1297-1299.	13.9	27
79	Cancer Signaling Drives Cancer Metabolism: AKT and the Warburg Effect. <i>Cancer Research</i> , 2021, 81, 4896-4898.	0.4	27
80	A Molecular Link between AKT Regulation and Chemotherapeutic Response. <i>Cancer Cell</i> , 2009, 16, 178-180.	7.7	26
81	Chewing the Fat on Tumor Cell Metabolism. <i>Cell</i> , 2010, 140, 28-30.	13.5	26
82	Insulin Signaling: Inositol Phosphates Get into the Akt. <i>Cell</i> , 2010, 143, 861-863.	13.5	26
83	Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1. <i>Molecular and Cellular Biology</i> , 2016, 36, 2384-2395.	1.1	25
84	Purine nucleotide depletion prompts cell migration by stimulating the serine synthesis pathway. <i>Nature Communications</i> , 2022, 13, 2698.	5.8	25
85	Therapeutic Trial of Metformin and Bortezomib in a Mouse Model of Tuberous Sclerosis Complex (TSC). <i>PLoS ONE</i> , 2012, 7, e31900.	1.1	24
86	Phosphatidylcholine Transfer Protein Interacts with Thioesterase Superfamily Member 2 to Attenuate Insulin Signaling. <i>Science Signaling</i> , 2013, 6, ra64.	1.6	23
87	The Mammalian Target of Rapamycin Complex 1 Regulates Leptin Biosynthesis in Adipocytes at the Level of Translation: The Role of the 5'-Untranslated Region in the Expression of Leptin Messenger Ribonucleic Acid. <i>Molecular Endocrinology</i> , 2008, 22, 2260-2267.	3.7	20
88	IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex. <i>JCI Insight</i> , 2020, 5, .	2.3	20
89	Adaptation to Starvation: Translating a Matter of Life or Death. <i>Cancer Cell</i> , 2013, 23, 713-715.	7.7	18
90	Hepatic mTORC1 signaling activates ATF4 as part of its metabolic response to feeding and insulin. <i>Molecular Metabolism</i> , 2021, 53, 101309.	3.0	16

#	ARTICLE	IF	CITATIONS
91	CASTORing New Light on Amino Acid Sensing. <i>Cell</i> , 2016, 165, 15-17.	13.5	14
92	Comment on "A Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation" Building a Model of the mTOR Signaling Network with a Potentially Faulty Tool. <i>Science Signaling</i> , 2012, 5, lc3; author reply lc4.	1.6	11
93	Zhang & Manning reply. <i>Nature</i> , 2016, 529, E2-E3.	13.7	11
94	Nutrient sensing lost in cancer. <i>Nature</i> , 2013, 498, 444-445.	13.7	9
95	mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci. <i>Scientific Reports</i> , 2017, 7, 16112.	1.6	9
96	Improved detection of synthetic lethal interactions in <i>Drosophila</i> cells using variable dose analysis (VDA). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10755-E10762.	3.3	8
97	Lysosomal catch-and-release controls mTORC1. <i>Nature Cell Biology</i> , 2018, 20, 996-997.	4.6	5
98	The TSC1-TSC2 Complex. <i>The Enzymes</i> , 2010, 28, 21-48.	0.7	4
99	Late-Onset Pharmacological or Dietary Interventions Improve Healthspan and Lifespan in Male and Female Mice. <i>Innovation in Aging</i> , 2020, 4, 125-125.	0.0	4
100	Mechanisms and consequences of hepatic regulation of mTORC1 by metformin. <i>Cancer & Metabolism</i> , 2014, 2, .	2.4	3
101	mTORC1 stimulates nucleotide synthesis through both transcriptional and post-translational mechanisms. <i>Cancer & Metabolism</i> , 2014, 2, .	2.4	3
102	Signalling protein protects the heart muscle from pressure-related stress. <i>Nature</i> , 2019, 566, 187-188.	13.7	3
103	The non-essential TSC complex component TBC1D7 restricts tissue mTORC1 signaling and brain and neuron growth. <i>Cell Reports</i> , 2022, 39, 110824.	2.9	3
104	Correction: Balancing Akt with S6K. <i>Journal of Cell Biology</i> , 2004, 167, 1255-1255.	2.3	2
105	IMPROVED HEALTHSPAN AND LIFESPAN WITH LATE ONSET PHARMACOLOGICAL OR DIETARY INTERVENTIONS IN MICE. <i>Innovation in Aging</i> , 2019, 3, S875-S875.	0.0	1
106	Oncogenic signaling upstream of mTORC1 drives lipogenesis and proliferation through SREBP. <i>Cancer & Metabolism</i> , 2014, 2, .	2.4	0
107	James R. Mitchell (1971-2020). <i>Cell Metabolism</i> , 2021, 33, 458-461.	7.2	0
108	Abstract SY29-02: The TSC-mTOR pathway and control of anabolic tumor cell metabolism. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
109	Abstract IA07: The TSC complex links PI3K to mTOR and cancer metabolism. , 2015, , .		0
110	Longevity-Extending MetAP2 Inhibitors Induce Caloric Restriction Through P53-Dependent Induction of GDF-15. Innovation in Aging, 2020, 4, 125-126.	0.0	0